The estimated Net Worth of John B. Landis is at least $93.7 millier dollars as of 9 February 2023. John Landis owns over 3,000 units of EyePoint Pharmaceuticals Inc stock worth over $93,708 and over the last 14 years he sold EYPT stock worth over $0. In addition, he makes $0 as Independent Director at EyePoint Pharmaceuticals Inc.
John has made over 5 trades of the EyePoint Pharmaceuticals Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he exercised 3,000 units of EYPT stock worth $24,660 on 9 February 2023.
The largest trade he's ever made was buying 40,000 units of EyePoint Pharmaceuticals Inc stock on 13 May 2019 worth over $69,600. On average, John trades about 5,954 units every 294 days since 2010. As of 9 February 2023 he still owns at least 11,400 units of EyePoint Pharmaceuticals Inc stock.
You can see the complete history of John Landis stock trades at the bottom of the page.
Dr. John B. Landis Ph.D. serves as Independent Director of the Company. Dr. Landis previously served as Senior Vice President, Pharmaceutical Sciences of Schering-Plough Corporation, a pharmaceutical company, from September 2003 until his retirement in October 2008. In that role, Dr. Landis led the global pharmaceutical sciences function of pharmacy, analytical chemistry, process chemistry, biotechnology, quality assurance, clinical supplies and devices. Prior to that, Dr. Landis served as Senior Vice President, Preclinical Development at Pharmacia Corporation from 1997 until 2003 and led the global preclinical functions of toxicology, drug metabolism and pharmacokinetics, pharmaceutical sciences, analytical chemistry and laboratory animal care. Dr. Landis also served as Vice President, Central Nervous System Psychiatry, Critical Care and Inflammation Development for Pharmacia & Upjohn from 1995 through 1997. Prior to that, Dr. Landis was employed by The Upjohn Company, where he held positions of increasing responsibility in the areas of analytical research, quality assurance and quality control. He is a current member of Purdue University’s Chemistry Leadership Council and Dean’s Leadership Council for the School of Science and serves on the Advisory Board of South West Michigan Life Science Venture Capital and NanoMed Scientific and on the board of directors of Metabolic Solutions Development Company. Over his career, Dr. Landis served on several other boards of directors, academic advisory panels and professional boards. Dr. Landis earned Ph.D. and M.S. degrees in Analytical Chemistry from Purdue University and a B.S. degree in Chemistry from Kent State University.
John Landis is 67, he's been the Independent Director of EyePoint Pharmaceuticals Inc since 2018. There are 2 older and 16 younger executives at EyePoint Pharmaceuticals Inc. The oldest executive at EyePoint Pharmaceuticals Inc is Goran Ando, 71, who is the Independent Chairman of the Board.
John's mailing address filed with the SEC is C/O EYEPOINT PHARMACEUTICALS, INC., 480 PLEASANT STREET, WATERTOWN, MA, 02472.
Over the last 7 years, insiders at EyePoint Pharmaceuticals Inc have traded over $67,100,515 worth of EyePoint Pharmaceuticals Inc stock and bought 21,910,863 units worth $111,404,456 . The most active insiders traders include Healthcare Partners, L.P.Ew..., Asset Management, Lp Chen B... et Ye Liu. On average, EyePoint Pharmaceuticals Inc executives and independent directors trade stock every 18 days with the average trade being worth of $1,746,068. The most recent stock trade was executed by Goran Ando on 21 August 2024, trading 5,000 units of EYPT stock currently worth $39,750.
psivida corp., (nasdaq: psdv) (asx: pva) headquartered in watertown, ma, develops tiny, sustained release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. psivida is currently focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, durasert™ and biosilicon™. the injectable, sustained release micro-insert iluvien® for the treatment of chronic diabetic macula edema (dme), licensed to alimera sciences, inc., has received marketing authorization in austria, france, germany, portugal, the u.k. spain, and italy. iluvien for dme has recently been approved in the us. psivida plans to institute pivotal phase iii clinical trials for the treatment of posterior uveitis with the same micro-insert as iluvien for dme. an investigator-sponsored clinical trial is ongoing for an injectable, bioerodible micro-insert to treat glaucoma and ocular hypertension. psivida's two fda-approved products, retisert®
EyePoint Pharmaceuticals Inc executives and other stock owners filed with the SEC include: